Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by The University of Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
James Chung-Man HO, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00956358
First received: August 9, 2009
Last updated: June 12, 2012
Last verified: June 2012
  Purpose

Haemopoietic stem cell transplantation (HSCT) has become a major life-saving treatment for many haematological conditions, mostly malignancies.

However, there are lots of potential complications that hinder the long-term success of HSCT, in which bronchiolitis obliterans syndrome (BOS) is one of such serious complications. Basically, BOS represents a form of graft-versus-host immunological damage of small airways (bronchioles), leading to progressive narrowing of small airways and thus obstructive lung function abnormalities. With progressive loss of lung function in BOS, patients after HSCT can be complicated by intractable respiratory failure that results in mortality. Up until now, there is still no reliable way to accurately predict or detect BOS early to allow pharmacological interventions.

Therefore there is intense interest in the search for biomarkers that can help to predict the occurrence of BOS after HSCT. Apart from biomarkers (e.g., cytokines) in blood, there has been recent development in the sampling of airway lining fluid by a non-invasive method, i.e., collection of exhaled breath condensate (EBC). In airway diseases such as asthma or chronic obstructive pulmonary disease, EBC has been found to have various cytokines which can serve as potential biomarkers of disease activity. Since BOS is largely a small airway disease, it becomes logical to investigate the profile of biomarkers in EBC as predictors for BOS after HSCT.

Therefore this study has been designed to look into the role of biomarkers in blood and EBC in early detection of BOS after HSCT.


Condition
Hematological Diseases

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study on Systemic and Airway Cytokines and Oxidative Stress in Patients Undergoing Haemopoietic Stem Cell Transplantation (HSCT)

Resource links provided by NLM:


Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Lung function indices [ Time Frame: Every 3 months until either 18 months post-HSCT or diagnosis of BOS ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Plasma, buffy coat, red blood cell and exhaled breath condensate samples.


Estimated Enrollment: 230
Study Start Date: March 2009
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Pre-HSCT
Haematological conditions requiring haemopoietic stem cell transplantation
Post-HSCT with BOS
Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
Control
Healthy HSCT donors

Detailed Description:

Haemopoietic stem cell transplantation (HSCT) has revolutionized the treatment of both haematological and perhaps some solid malignancies. However, despite recent technological advancements, HSCT is still associated with significant mortality and morbidities.

Apart from various infective complications in early stage post-HSCT, bronchiolitis obliterans syndrome (BOS) has been a well-known late complication that can result in high mortality. It has been mostly associated with those who develop chronic graft-versus-host disease after allogeneic HSCT. Clinically, the diagnosis of BOS is largely based on demonstration of obstructive lung function abnormalities and air-trapping in computed tomography scan of thorax. Pathologically, bronchiolitis obliterans is characterized by both inflammatory and fibrotic reactions in the small bronchioles leading to subsequent obliteration. Upon diagnosis of BOS post-HSCT, inhaled corticosteroid (with or without bronchodilators) is commonly prescribed as anti-inflammatory agent, though with undocumented clinical efficacy. Unfortunately, there is still a lack of reliable biomarkers that can predict or allow early detection of BOS, preferably in the early and potentially reversible stage of development of BOS.

Apart from measuring circulating biomarkers in blood, exhaled breath condensate (EBC) has recently emerged as a non-invasive sampling method for real-time analysis and evaluation of oxidative stress biomarkers in the lower respiratory tract airways, especially in various lung diseases including asthma, chronic obstructive pulmonary disease, and lung cancer. As bronchiolitis obliterans is predominantly a disease of the small bronchioles, it is highly likely to be associated with changes in various inflammatory and oxidative stress biomarkers in EBC. However, the role of measuring EBC biomarkers in predicting the occurrence of BOS after HSCT has not been studied. Therefore, the current study aims to evaluate the temporal changes of various oxidative stress biomarkers and cytokines in EBC and blood in patients with haematological conditions who undergo allogeneic HSCT, with regard to the subsequent development of BOS.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Haematological conditions requiring HSCT and healthy HSCT donors will be identified from Bone Marrow Transplatation (BMT) Unit and post-HSCT patients with BOS will be identified from Respiratory Medicine clinics at Queen Mary Hospital.

Criteria

Inclusion Criteria:

  • Haematological conditions requiring HSCT (either autologous or allogeneic with sibling donor), post-HSCT BOS, or healthy HSCT donors
  • Life expectancy > 12 weeks

Exclusion Criteria:

  • Respiratory failure requiring use of supplemental oxygen therapy
  • Known airway diseases including asthma, chronic obstructive pulmonary disease and bronchiectasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00956358

Contacts
Contact: Chung-man James Ho 852-28554999 jhocm@hkucc.hku.hk

Locations
Hong Kong
Queen Mary Hospital Recruiting
Hong Kong, Hong Kong
Contact: Chung-man James Ho    852-28554999    jhocm@hkucc.hku.hk   
Principal Investigator: Chung-man James Ho, MD,FRCP         
Sub-Investigator: Kwan-ling Julie Wang, MBBS ,MRCP         
Sub-Investigator: Kwok-wai Albert Lie, MBBS,FRCP         
Sub-Investigator: Wing-yan Thomas Au, MD,FRCP         
Sub-Investigator: Hin-suen Raymond Liang, MD,FRCP         
Sponsors and Collaborators
The University of Hong Kong
Investigators
Principal Investigator: Chung-man James Ho The University of Hong Kong
  More Information

No publications provided

Responsible Party: James Chung-Man HO, Clinical Assistant Professor, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT00956358     History of Changes
Other Study ID Numbers: UW 09-107
Study First Received: August 9, 2009
Last Updated: June 12, 2012
Health Authority: Hong Kong: Ethics Committee

Keywords provided by The University of Hong Kong:
bronchiolitis obliterans syndrome

Additional relevant MeSH terms:
Hematologic Diseases

ClinicalTrials.gov processed this record on November 23, 2014